The Specific Inhibition of Influenza A Virus Maturation by Amantadine: An Electron Microscopic Examination

References

1. Bean W. J., Threlkeld S. C., Webster R. G. 1989; Biologic potential of amantadine-resistant influenza A virus in an avian model. Journal of Infectious Diseases 159:1050–1056
   [Google Scholar]
2. Belshe R. B., Hall-Smith M., Hall C. B., Betts R., Hay A. J. 1988; Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. Journal of Virology 62:1508–1512
   [Google Scholar]
3. Bukrinskaya A. G., Vorkunova N. K., Pushkarskaya N. L. 1982; Uncoating of a rimantadine-resistant variant of influenza virus in the presence of rimantadine. Journal of General Virology 60:61–66
   [Google Scholar]
4. Dolin R., Reichman R. C., Madore H. P., Maynard R., Linton P. N., Webber-Jones J. 1982; A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. New England Journal of Medicine 307:580–584
   [Google Scholar]
5. Hall C. B., Dolin R., Gala C. L., Markovitz D. M., Zhang Y. Q., Madore P. H., Disney F. A., Talpey W. B., Green J. L., Francis A. B., Pichichero M. E. 1987; Children with influenza A infection: treatment with rimantadine. Pediatrics 80:275–282
   [Google Scholar]
6. Hay A. J., Kennedy N. C. T., Skehel J. J., Appleyard G. 1979; The matrix protein gene determines amantadine-sensitivity of influenza viruses. Journal of General Virology 42:189–191
   [Google Scholar]
7. Hay A. J., Wolstenholme A. J., Skehel J. J., Smith M. H. 1985; The molecular basis of the specific anti-influenza action of amantadine. EMBO Journal 4:3021–3024
   [Google Scholar]
8. Hay A. J., Zambon M. C., Wolstenholme A. J., Skehel J. J., Smith M. H. 1986; Molecular basis of resistance of influenza A viruses to amantadine. Journal of Antimicrobial Chemotherapy 18: supplement B 19–29
   [Google Scholar]
9. Hayden F. G., Belshe R. B., Clover R. D., Hay A. J., Oakes M. G., Soo W. 1989; Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. New England Journal of Medicine 321:1696–1702
   [Google Scholar]
10. Kato N., Eggers H. J. 1969; Inhibition of uncoating of fowl plague virus by 1-adamantanamine hydrochloride. Virologv 37:632–641
    [Google Scholar]
11. Lubeck M. D., Schulman J. L., Palese P. 1978; Susceptibility of influenza A viruses to amantadine is influenced by the gene coding for M protein. Journal of Virology 28:710–716
    [Google Scholar]
12. Palese P., Compans R. W. 1976; Inhibition of influenza virus replication in tissue culture by 2-deoxy-2, 3-dehydro-N-trifluoro-acetylneuraminic acid (FANA): mechanism of action. Journal of General Virology 33:159–163
    [Google Scholar]
13. Palese P., Tobita K., Ueda M. 1974; Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61:397–410
    [Google Scholar]
14. Ruigrok R. W. H., Cremers A. F. M., Beyer W. E. P., De Ronde-Verloop F. M. 1984; Changes in the morphology of influenza virus particles induced at low pH. Archives of Virology 82:181–194
    [Google Scholar]
15. Ruigrok R. W. H., Wrigley N. G., Calder L. J., Cusack S., Wharton S. A., Brown E. B., Skehel J. J. 1986; Electron microscopy of the low pH structure of influenza virus haemagglutinin. EMBO Journal 5:41–49
    [Google Scholar]
16. Scholtissek C., Faulkner G. P. 1979; Amantadine-resistant and sensitive influenza A strains and recombinants. Journal of General Virology 44:807–815
    [Google Scholar]
17. Skehel J. J., Bayley P. M., Brown E. B., Martin S. R., Waterfield M. D., White J. M., Wilson I. A., Wiley D. C. 1982; Changes in the conformation of influenza virus haemagglutinin at the pH optimum of virus-mediated fusion. Proceedings of the National Academy of Sciences, U.S.A. 79:968–972
    [Google Scholar]
18. Sugrue R. J., Bahadur G., Zambon M. C., Hall-Smith M., Douglas A. R., Hay A. J. 1990; Specific structural alteration of the influenza haemagglutinin by amantadine. EMBO Journal 9: (in press)
    [Google Scholar]
19. Tominack R. L., Hayden F. G. 1987; Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infectious Disease Clinics of North America 1:459–478
    [Google Scholar]
20. Van Voris L. P., Betts R. F., Hayden F. G., Christmas W. A., Douglas R. G. 1981; Successful treatment of naturally occurring influenza A/USSR/77 H1N1. Journal of the American Medical Association 245:1128–1131
    [Google Scholar]
21. Wiley D. C., Wilson I. A., Skehel J. J. 1981; Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature, London 289:373–378
    [Google Scholar]
22. Wingfield W. L., Pollack D., Grunert R. R. 1969; Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. New England Journal of Medicine 281:579–584
    [Google Scholar]
23. Zebedee S. L., Lamb R. A. 1989; Growth restriction of influenza A virus by M₂ protein antibody is genetically linked to the M₁ protein. Proceedings of the National Academy of Sciences, U.S.A. 86:1061–1065
    [Google Scholar]